Discovery Labs is developing its SRT™ platform with the intent to create a completely new therapeutic approach in the treatment of respiratory disease.

Product introduction begins with anticipated U.S. FDA approval of SURFAXIN^®, followed by the potential launch of multiple line extensions involving a variety of dosage forms and novel indications of usage.

AEROSURF™, Discovery Labs' aerosolized surfactant candidate, represents a potential transformation in respiratory critical care by reducing or eliminating complications associated with mechanical ventilation.